Langerhans cell histiocytosis: temporal bone invasion in an adult.
Physical examination showed a mass filling the patient's left external auditory canal. A biopsy in clinic was deferred as there was concern that this mass might be a vascular tumor, making hemostasis difficult to achieve in the office setting. Magnetic resonance imaging (MRI) demonstrated a large, enhancing mass in the left mastoid that extended into the external auditory canal (figure 1). There were aggressive features noted, such as bony erosion and possible dural involvement, but the ossicles were spared.
At surgery, massive bone destruction was found along the base of the skull and the inferior part of the mastoid that extended into the superior aspect of the musculature of the neck. The destructive lesion was adherent to the dura but did not transgress it. The tumor was debulked and grossly dissected away from the dura. No cerebrospinal fluid leak was encountered during the dissection, and the facial nerve was found to be intact. The surgical defect was obliterated using an occipital myosubcutaneous flap.
Microscopic examination of the biopsy revealed clusters and sheets of Langerhans cells (figure 2). The tumor cells had grooved and irregularly contorted nuclei with inconspicuous nucleoli. Admixed eosinophils were also noted. The tumor cells showed immunoreactivity for S-100 protein and CD la, confirming a diagnosis of Langerhans cell histiocytosis (LCH).
Radiographic imaging--including computed tomography (CT) of the chest, abdomen, and pelvis and an osseous survey--were ordered for further evaluation and to determine the extent of the disease. The imaging demonstrated disseminated disease with a destructive lesion of the right ilium and abnormal soft tissue in the bilateral perinephric space. The oncologists recommended systemic chemotherapy because further surgical debulking was no longer practical. The patient expired several months later from complications of her disease and her comorbid conditions, as well as poor compliance.
LCH is caused by the proliferation and accumulation of a specific histiocyte, the Langerhans cell. The disease can involve any bone, but most lesions occur in the flat bones of the skull, pelvis, spine, mandible, and ribs. (1) Imaging of the skull will often reveal lytic lesions with scalloped edges. CT is better suited for demonstrating bone detail and MRI for bone marrow and soft-tissue involvement.
Patients with limited initial involvement of the temporal bone have a better prognosis on long-term follow-up than do patients with the multisystemic form of LCH. (2) Temporal bone involvement is bilateral in 31% of cases, and otologic symptoms were the initial presentation in 25% of these cases. (3)
Despite the characteristic of extensive destruction of the temporal bone in this disease, the facial nerve is surprisingly resistant to destruction, and facial nerve palsy is rare. If present, facial nerve palsies are likely caused by compromise of blood supply to the nerve. (3)
Histopathologically, LCH is characterized by proliferation of atypical Langerhans cells that form granulomas. Langerhans cells have cytoplasmic inclusion bodies known as Birbeck granules; a definitive diagnosis requires electron microscopy of Birbeck granules or CD 1 antigenic determinants by immunohistochemistry. (3)
Treatment of temporal bone lesions remains controversial. Surgery is required to make the histologic diagnosis but does not improve outcome. Treatment options include intralesional steroids, systemic steroids, systemic chemotherapy, and surgical curettage. Other authors have reported good local disease control with low-dose radiotherapy. (4)
LCH is rare in adults compared to the pediatric population. The age at presentation does not appear to predict the severity or course of the disease in adults, in contrast to children. Multisystemic disease is the only known prognostic factor. Although rare in adults, LCH is an important disease process that needs to be considered in the differential in patients presenting with refractory otologic symptoms.
This case report was reviewed and approved by the Institutional Review Board of Wake Forest University Baptist Medical Center.
(1.) Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans' cell histiocytosis: Pathology, imaging and treatment of skeletal involvement. Pediatr Radiol2005;35(2): 103-15.
(2.) Fernandez-Latorre F, Menor-Serrano F, Alonso-Charterina S, Arenas-Jimenez J. Langerhans' cell histiocytosis of the temporal bone in pediatric patients: Imaging and follow-up. AJR Am J Roentgenol 2000;174(1):217-21.
(3.) Whitaker EG, Cerenko D, Muller S, Hudgins P. Multifocal langerhans' [sic] cell histiocytosis involving bilateral temporal bones, lungs, and hypothalamus in an adult. Skull Base Surg 1999;9(1): 51-6.
(4.) Zlodre JK, Rennie AT, Ramsden JD. Langerhans' cell histiocytosis of the temporal bone: Successful treatment of sensorineural hearing loss with low-dose radiotherapy. J Laryngol Otol2009;123(6): 676-9.
Richard L. Alexander MD, PhD, MBA; Mary L. Worthen, BS; Changlee S. Pang, MD; John S. May, MD
From the Department of Otolaryngology, Head and Neck Surgery (Dr. Alexander, Ms. Worthen, and Dr. May) and the Department of Pathology (Dr. Pang), Wake Forest University School of Medicine, Winston-Salem, N.C. Previous presentation: This case was given as an oral presentation at the North Carolina South Carolina Society of Otolaryngology, Head and Neck surgery in 2012.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||IMAGING CLINIC|
|Author:||Alexander, Richard L.; Worthen, Mary L.; Pang, Changlee S.; May, John S.|
|Publication:||Ear, Nose and Throat Journal|
|Article Type:||Case study|
|Date:||Oct 1, 2013|
|Previous Article:||Office assessment of vocal fold hypomobility.|
|Next Article:||Undifferentiated thyroid carcinoma.|